Patients with type 1 diabetes (T1D) may develop severe outcomes during COVID-19 disease, but their ability to generate an immune response against the SARS-CoV-2 messenger RNA (mRNA) vaccines remains to be established. Here we evaluated the safety, immunogenicity and glycometabolic effects of the SARS-CoV-2 mRNA vaccines in patients with T1D. A total of 375 patients, 326 with T1D and 49 non-diabetics, who received two doses of the SARS-CoV-2 mRNA vaccines (mRNA-1273, BNT162b2) between March and April 2021 at the ASST FBF-Sacco Milan, Italy, were included in this monocentric observational study (NCT04905823). Local and systemic adverse events were reported in both groups after SARS-CoV-2 mRNA vaccination without statistical differences between them. While both T1D patients and non-diabetic subjects exhibited a parallel increase in anti-SARS-CoV-2S titers after vaccination, the vast majority of T1D patients (70% and 78% respectively) did not show any increase in the SARS-CoV-2-specific cytotoxic response as compared to the robust increased observed in all non-diabetic subjects. A reduced secretion of the T cell-related cytokines IL-2 and TNF-alpha in vaccinated patients with T1D was also observed. No glycometabolic alterations were evident in patients with T1D using continuous glucose monitoring during follow-up. Administration of the SARS-CoV-2 mRNA vaccine is associated with an impaired cellular SARS-CoV-2-specific cytotoxic immune response in T1D patients.

Immunogenicity and safety of SARS-CoV-2 mRNA vaccines in a cohort of patients with type 1 diabetes / F. D'Addio, G. Sabiu, V. Usuelli, E. Assi, A. Abdelsalam, A. Maestroni, A. Joe Seelam, M. Ben Nasr, C. Loretelli, D. Mileto, G. Rossi, I. Pastore, L. Montefusco, P.S. Morpurgo, L. Plebani, A. Rossi, E. Chebat, A.M. Bolla, E. Lunati, C. Mameli, M. Macedoni, S. Antinori, S. Rusconi, M. Gallieni, C. Berra, F. Folli, M. Galli, M. Rita Gismondo, G. Vincenzo Zuccotti, P. Fiorina. - In: DIABETES. - ISSN 0012-1797. - 71:8(2022 Aug), pp. 1800-1806. [10.2337/db22-0053]

Immunogenicity and safety of SARS-CoV-2 mRNA vaccines in a cohort of patients with type 1 diabetes

F. D'Addio
Primo
;
G. Sabiu
Secondo
;
V. Usuelli;E. Assi;A. Abdelsalam;A. Maestroni;A. Joe Seelam;M. Ben Nasr;C. Loretelli;D. Mileto;G. Rossi;I. Pastore;P.S. Morpurgo;A. Rossi;E. Lunati;C. Mameli;M. Macedoni;S. Antinori;S. Rusconi;M. Gallieni;F. Folli;M. Galli;M. Rita Gismondo;G. Vincenzo Zuccotti
Penultimo
;
P. Fiorina
Ultimo
2022

Abstract

Patients with type 1 diabetes (T1D) may develop severe outcomes during COVID-19 disease, but their ability to generate an immune response against the SARS-CoV-2 messenger RNA (mRNA) vaccines remains to be established. Here we evaluated the safety, immunogenicity and glycometabolic effects of the SARS-CoV-2 mRNA vaccines in patients with T1D. A total of 375 patients, 326 with T1D and 49 non-diabetics, who received two doses of the SARS-CoV-2 mRNA vaccines (mRNA-1273, BNT162b2) between March and April 2021 at the ASST FBF-Sacco Milan, Italy, were included in this monocentric observational study (NCT04905823). Local and systemic adverse events were reported in both groups after SARS-CoV-2 mRNA vaccination without statistical differences between them. While both T1D patients and non-diabetic subjects exhibited a parallel increase in anti-SARS-CoV-2S titers after vaccination, the vast majority of T1D patients (70% and 78% respectively) did not show any increase in the SARS-CoV-2-specific cytotoxic response as compared to the robust increased observed in all non-diabetic subjects. A reduced secretion of the T cell-related cytokines IL-2 and TNF-alpha in vaccinated patients with T1D was also observed. No glycometabolic alterations were evident in patients with T1D using continuous glucose monitoring during follow-up. Administration of the SARS-CoV-2 mRNA vaccine is associated with an impaired cellular SARS-CoV-2-specific cytotoxic immune response in T1D patients.
Settore MED/13 - Endocrinologia
Settore MED/50 - Scienze Tecniche Mediche Applicate
Settore MED/46 - Scienze Tecniche di Medicina di Laboratorio
ago-2022
21-ago-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
D'Addio et al. - 2022 - Immunogenicity and safety of SARS-CoV-2 mRNA vaccines in a cohort of patients with type 1 diabetes.pdf

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 639.33 kB
Formato Adobe PDF
639.33 kB Adobe PDF Visualizza/Apri
db220053.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 709.36 kB
Formato Adobe PDF
709.36 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/929634
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 18
social impact